Rallybio (RLYB) Competitors $0.59 +0.01 (+1.47%) Closing price 04:00 PM EasternExtended Trading$0.59 0.00 (0.00%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. KALA, OVID, OKYO, VXRT, WHWK, ATRA, QNCX, ABOS, PYXS, and IRDShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include KALA BIO (KALA), Ovid Therapeutics (OVID), OKYO Pharma (OKYO), Vaxart (VXRT), Whitehawk Therapeutics (WHWK), Atara Biotherapeutics (ATRA), Quince Therapeutics (QNCX), Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Its Competitors KALA BIO Ovid Therapeutics OKYO Pharma Vaxart Whitehawk Therapeutics Atara Biotherapeutics Quince Therapeutics Acumen Pharmaceuticals Pyxis Oncology Opus Genetics Rallybio (NASDAQ:RLYB) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Do institutionals & insiders believe in RLYB or KALA? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 8.7% of Rallybio shares are owned by company insiders. Comparatively, 8.3% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is RLYB or KALA more profitable? KALA BIO has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Rallybio's return on equity of -71.66% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Rallybio-5,473.33% -71.66% -65.06% KALA BIO N/A -686.43%-76.81% Which has more volatility and risk, RLYB or KALA? Rallybio has a beta of -1.1, meaning that its share price is 210% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.81, meaning that its share price is 281% less volatile than the S&P 500. Does the media prefer RLYB or KALA? In the previous week, Rallybio and Rallybio both had 4 articles in the media. KALA BIO's average media sentiment score of 0.56 beat Rallybio's score of 0.53 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, RLYB or KALA? KALA BIO has higher revenue and earnings than Rallybio. KALA BIO is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$640K38.26-$57.78M-$0.94-0.62KALA BIO$3.89M26.22-$38.51M-$6.79-2.14 Do analysts prefer RLYB or KALA? Rallybio currently has a consensus target price of $5.00, indicating a potential upside of 753.24%. KALA BIO has a consensus target price of $13.00, indicating a potential downside of 10.53%. Given Rallybio's higher possible upside, analysts plainly believe Rallybio is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryRallybio beats KALA BIO on 9 of the 16 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.49M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.6221.0383.0126.65Price / Sales38.26379.60503.06163.66Price / CashN/A43.5325.7028.92Price / Book0.538.1210.796.52Net Income-$57.78M-$53.35M$3.29B$266.21M7 Day Performance4.61%0.06%0.03%-0.75%1 Month Performance10.78%7.09%7.09%3.84%1 Year Performance-47.21%11.93%50.11%24.40% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio3.2806 of 5 stars$0.59+1.5%$5.00+753.2%-47.5%$24.49M$640K-0.6240News CoverageShort Interest ↓Gap UpKALAKALA BIO2.8405 of 5 stars$12.68+13.0%$13.00+2.5%+148.1%$88.49M$3.89M-1.8630News CoverageAnalyst UpgradeHigh Trading VolumeOVIDOvid Therapeutics4.3825 of 5 stars$1.22-4.4%$3.10+153.3%+22.0%$87.11M$570K-2.3160Gap DownOKYOOKYO Pharma3.2378 of 5 stars$2.31-1.7%$7.00+203.0%+97.4%$86.88MN/A0.007News CoveragePositive NewsShort Interest ↓VXRTVaxart2.4166 of 5 stars$0.37-4.6%$2.00+437.5%-54.2%$85.18M$47.40M-1.38120News CoverageGap DownWHWKWhitehawk TherapeuticsN/A$1.80-0.3%N/AN/A$84.83M$25.98M-30.0040Positive NewsGap DownATRAAtara Biotherapeutics4.5213 of 5 stars$11.98-0.6%$21.00+75.4%+85.5%$84.06M$128.94M-27.85330News CoverageQNCXQuince Therapeutics3.725 of 5 stars$1.57-2.2%$8.14+420.3%+132.3%$84.06MN/A-1.4460Positive NewsABOSAcumen Pharmaceuticals2.8449 of 5 stars$1.35-0.4%$7.00+417.0%-43.3%$82.01MN/A-0.5920PYXSPyxis Oncology1.3699 of 5 stars$1.29+0.8%$8.67+571.8%-57.3%$80.01M$16.15M-0.8160Analyst ForecastGap UpIRDOpus Genetics1.9675 of 5 stars$1.32+8.2%$7.33+455.6%N/A$79.38M$10.99M-0.6914News CoveragePositive NewsGap Up Related Companies and Tools Related Companies KALA BIO Alternatives Ovid Therapeutics Alternatives OKYO Pharma Alternatives Vaxart Alternatives Whitehawk Therapeutics Alternatives Atara Biotherapeutics Alternatives Quince Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Pyxis Oncology Alternatives Opus Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts